Gene replacement therapy for Lafora disease

In the Epm2a-/- mouse model

AUTHORS

Luis Zafra-Puerta, Daniel F. Burgos, Nerea Iglesias-Cabeza, Juan González-Fernández, Gema Sánchez-Martín, Marina P. Sánchez, José M. Serratosa

RESEARCH SIMPLIFIED BY Spencer Nguyen

AIMS AND METHODS

Gene replacement therapy is a recent medical technique used to treat genetic disorders by replacing a missing or faulty gene with a normal, healthy one. This approach targets the root cause of the disease, addressing the underlying genetic defect rather than merely alleviating symptoms.

In this article, researchers have used Epm2a-/- knock-out mouse models to test gene replacement therapy by administering the EPM2A gene through intracerebroventricular (ICV) injections. The EPM2A gene encodes for the protein laforin, which plays a crucial role in regulating how sugar is stored as glycogen. In the absence of laforin, glycogen begins to accumulate, leading to the formation of harmful Lafora bodies. Gene replacement therapy aims to introduce the functional EPM2A gene into patients with mutations that prevent the production of laforin. Researchers hope to demonstrate whether the restoration of laforin in mice prevents the formation of Lafora bodies and addresses the underlying cause of Lafora disease (LD).

RESULTS

Intracerebroventricular (ICV) injections of rAAV-hEPM2A, a vector containing EPM2A, restored the production of laforin in the treated mice. When treated at a young age, this treatment effectively prevented the formation of Lafora bodies in the brain, while also reducing epileptic activity. Moreover, the therapy delayed the onset of memory decline and alleviated motor impairments. These promising outcomes highlight the potential of gene replacement therapy as a viable treatment for LD.

CONCLUSION

To conclude, this study demonstrates the significant therapeutic impact of gene replacement in a mouse model of LD. Early symptomatic stage treatment reduced neuroinflammation and Lafora body formation, delayed memory and motor decline, improved motor coordination, and reduced epileptic activity. These findings highlight the potential of gene replacement therapy to address neurological dysfunctions in LD with patients with a mutation in the EPM2A gene, opening new treatment avenues.

Gene replacement therapy for Lafora disease in the Epm2a-/- mouse model Luis Zafra-Puerta, Daniel F. Burgos, Nerea Iglesias-Cabeza, Juan González-Fernández, Gema Sánchez-Martín, Marina P. Sánchez, José M. Serratosa
bioRxiv 2023.12.14.571636; doi: https://doi.org/10.1101/2023.12.14.571636.
This article is a preprint and has not been certified by peer review